<DOC>
	<DOC>NCT00595101</DOC>
	<brief_summary>To investigate dose response, safety and efficacy of PF-03187207 in patients with primary open-angle glaucoma or ocular hypertension</brief_summary>
	<brief_title>A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Man or woman at least 20 years of age Diagnosis of primary openangle glaucoma or ocular hypertension in one or both eyes. Closed/barely open anterior chamber angle or a history of acute angle closure in either eye Contraindications to latanoprost and nitric oxide treatment Known latanoprost nonresponders</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>